Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment

描述（由申请人提供）：目前，导管原位癌（DCIS）占筛查人群中新诊断乳腺癌的20-30%。由于无法对复发和疾病进展高风险的DCIS人群进行分层，目前许多女性过度治疗，尽管进行了手术和辅助干预，但约10-15%的患者仍有疾病复发。初步和已发表的数据表明，大部分DCIS病变表现出ErbB 2和RB通路的改变。然而，没有研究调查两种途径异常在同一DCIS病变中的影响。在这个应用中我们使用函数研究，将：1.明确RB通路在ErbB 2过表达DCIS进展中的作用; 2.确定RB和ErbB 2状态如何影响对放射治疗的反应。

DESCRIPTION (provided by applicant): Currently ductal carcinoma in situ (DCIS) accounts for 20-30% of newly diagnosed breast cancers in screened populations. Because of the inability to stratify the DCIS populations at high risk for recurrence and disease progression, many women are currently over-treated and approximately 10-15% patients have disease recurrence despite surgical and adjuvant interventions. Preliminary and published data indicate that a large fraction of DCIS lesions exhibits alterations in the ErbB2 and RB-pathways. However there are no studies investigating effects of both pathways abnormalities in the same DCIS lesion. In this application we using functional studies, will: 1. Define role of RB pathway in progression of ErbB2 overexpressing DCIS and 2. Determine how RB and ErbB2 status impacts response to radiation therapy.